Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Rhea-AI Summary
Kymera Therapeutics (NASDAQ: KYMR) will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 8:10 a.m. ET.
A live webcast and archived replay will be available in the Investors “News and Events” section of the company website.
Positive
- None.
Negative
- None.
News Market Reaction – KYMR
In the May 27 session, KYMR gained 1.15%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | KT-621 Phase 1b data | Positive | -2.7% | Phase 1b KT-621 data with robust STAT6 degradation and efficacy signals. |
| May 06 | Investor conferences | Neutral | +4.3% | Announcement of May healthcare conference fireside chat participation. |
| May 05 | KT-579 preclinical data | Positive | -1.1% | Preclinical KT-579 IBD data showing reduced disease activity and cytokine inhibition. |
| May 05 | Jeito leadership changes | Neutral | -1.1% | Jeito Capital leadership appointments in life-sciences investment management. |
| Apr 30 | Q1 2026 earnings | Neutral | -0.5% | Q1 2026 results with higher collaboration revenue, wider loss, and large cash balance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive R&D updates (KT-621, KT-579) previously coincided with modest negative next-day moves, while conference participation and earnings updates saw smaller, mixed reactions.
Over the past month, Kymera reported several R&D and financial milestones. On Apr 30, Q1 2026 results highlighted $34.4M collaboration revenue, a $69.2M net loss, and $1.55B in cash, alongside a $45M KT-200 milestone. Early May brought new preclinical KT-579 data and Phase 1b KT-621 results in atopic dermatitis, both with biomarker and efficacy signals. The company also regularly participates in investor conferences. Today’s Jefferies fireside chat fits this pattern of ongoing investor outreach rather than a new clinical or financial catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on June 3, 2026, at 8:10 a.m. ET.
A live webcast of the presentation will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Investor Contact:
Justine Koenigsberg
investors@kymeratx.com
857-285-5300
Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300
